FDA on the Compounded Semaglutide
The FDA warns that compounded semaglutide is not FDA-approved, meaning it has not been reviewed for safety, effectiveness, or quality. Following the resolution of drug shortages for Ozempic/Wegovy, the FDA has limited the legal sale of compounded versions. Risks include overdoses from dosing errors (5-20 times the intended dose), mislabeled products, and unknown ingredients.
The U.S. Food and Drug Administration (.gov)+5
Key FDA Findings & Concerns (as of March 2026):
- Shortage Resolution: The FDA declared the shortage of GLP-1 drugs resolved, effectively ending the allowance for pharmacies . . .
This content is for paid subscribers.Impacting News March 4, 2026
